Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules
April 17, 2024 02:00 ET
|
Essential Pharma
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules Reminyl® is an established CNS brand for the symptomatic treatment of mild to moderately severe...
Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma
April 09, 2024 02:00 ET
|
Essential Pharma
Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma First development-stage asset to be added to the Essential Pharma...
Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva
January 08, 2024 02:00 ET
|
Essential Pharma
Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva Colobreathe® is an inhaled antibiotic for the management of chronic Pseudomonas aeruginosa infections in...
Essential Pharma appoints Lee Morley as Non-Executive Director to the Board
June 21, 2023 02:00 ET
|
Essential Pharma
Essential Pharma appoints Lee Morley as Non-Executive Director to the Board Zug, Switzerland & Egham, UK – 21 June 2023 – Essential Pharma, an international specialty pharma group focused on...
Essential Pharma Announces the Appointment of Emma Johnson as Chief Executive Officer
May 24, 2023 02:00 ET
|
Essential Pharma
Essential Pharma Announces the Appointment of Emma Johnson as Chief Executive Officer Zug, Switzerland & Egham, UK – 24 May 2023 – Essential Pharma, an international specialty pharma company...
Autorisation de mise sur le marché françaises de IOPIDINE® 1 % (Apraclonidine) transférée à Essential Pharma en adéquation avec les besoins médicaux et la stratégie d'expansion de l'entreprise
January 19, 2023 02:00 ET
|
Essential Pharma
Autorisation de mise sur le marché françaises de IOPIDINE® 1 % (Apraclonidine) transférée à Essential Pharma en adéquation avec les besoins médicaux et la stratégie d'expansion de l'entreprise Une...
UK marketing authorisations for IOPIDINE® (apraclonidine) fully transferred to Essential Pharma as change in UK NICE guidelines for glaucoma treatment expected to lead to increase in patients’ need for product
December 15, 2022 07:06 ET
|
Essential Pharma
UK marketing authorisations for IOPIDINE® (apraclonidine) fully transferred to Essential Pharma as change in UK NICE guidelines for glaucoma treatment expected to lead to increase in patients’ need...
Essential Pharma Announces the Acquisition of HALDOL®
December 07, 2022 02:00 ET
|
Essential Pharma
Essential Pharma Announces the Acquisition of HALDOL® HALDOL® is a first-generation ‘typical’ antipsychotic for the treatment of schizophrenia and some other psychiatric conditions The acquisition...